What Is GLP-2? Mechanism, Uses, and How It Relates to Weight

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

"What is GLP-2" is a common follow-on question from people learning about GLP-1 receptor agonists. GLP-2 (glucagon-like peptide-2) is a related incretin peptide co-secreted with GLP-1 from intestinal L-cells, but it acts on a separate receptor and serves a distinct biological role. This article explains what GLP-2 is, how it works, how it differs from GLP-1, and why it is relevant to the broader peptide landscape. No prescribing or treatment direction appears here — that is your prescribing provider's role.

What GLP-2 is

GLP-2 is a 33-amino-acid peptide hormone encoded by the proglucagon gene — the same gene that produces GLP-1 and glucagon. It is co-secreted from intestinal L-cells in response to nutrient ingestion. GLP-2 acts on the GLP-2 receptor (GLP2R) expressed primarily in the gut and is best known for promoting intestinal mucosal growth, enhancing nutrient absorption, and supporting gut barrier integrity.

How GLP-2 works

GLP-2 binds the GLP-2 receptor in the intestinal epithelium, stimulating crypt cell proliferation and inhibiting apoptosis — effects that support mucosal growth and maintain the absorptive surface area of the small intestine. GLP-2 also slows gastric emptying and reduces intestinal permeability. Unlike GLP-1, GLP-2 does not meaningfully engage pancreatic insulin secretion or central appetite pathways.

How GLP-2 relates to weight management

GLP-2 does not directly suppress appetite or drive weight loss the way GLP-1 receptor agonists do. Its primary role is intestinal trophic support. However, improved gut mucosal integrity and nutrient absorption can be relevant variables in metabolic health. Teduglutide (Gattex/Revestive) is an FDA-approved GLP-2 analogue indicated for short bowel syndrome, not for weight management.

Safety considerations

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Contact a provider for severe or persistent abdominal pain (possible pancreatitis), right-upper-quadrant pain with fever (possible gallbladder disease), persistent vomiting with dehydration, signs of hypoglycemia, or any allergic reaction symptom. Severe symptoms warrant urgent or emergency care.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R, TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: What Is GLP-1?, GLP-1 Receptor Agonist, GLP-1 Drugs, GLP-1 Hormone.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology underneath every decision. Take the Precision Peptide Genetic Test, or explore the protocol directly.

Frequently Asked Questions

What is GLP-2 used for?

GLP-2 analogues are used therapeutically for conditions involving intestinal mucosal insufficiency. Teduglutide is FDA-approved for short bowel syndrome. GLP-2 is not a weight-loss agent and is not in the GLP-1 receptor agonist class.

How does GLP-2 differ from GLP-1?

GLP-1 and GLP-2 are co-secreted from the same intestinal L-cells but act on different receptors with distinct effects: GLP-1 modulates insulin secretion, appetite, and gastric emptying; GLP-2 primarily supports intestinal mucosal growth and gut barrier integrity. The two peptides are not interchangeable in either mechanism or clinical application.

Does genetic testing inform GLP-2 pathway biology?

No. The Precision Peptide Genetic Test does not predict response to any specific dose of any specific medication. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies at every step of the titration schedule.

What side effects should I watch for at Glp-1 2 mg?

GLP-2 analogues such as teduglutide carry their own safety profile distinct from GLP-1 receptor agonists. Common reported effects include gastrointestinal symptoms, fluid retention, and injection-site reactions. Consult a healthcare provider and the prescribing information for any GLP-2 analogue before use.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education